Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JD HEALTH
06618
5
ALI HEALTH
00241
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -7.11%1.7B | -6.13%3.68B | -0.96%1.83B | 3.19%3.92B | 1.94%1.85B | 628.64%3.8B | 650.73%1.81B | 28.94%521.92M | --241.17M | 15.16%404.79M |
| Operating income | -7.11%1.7B | -6.13%3.68B | -0.96%1.83B | 3.19%3.92B | 1.94%1.85B | 628.64%3.8B | 650.73%1.81B | 28.94%521.92M | 241.17M | 15.16%404.79M |
| Cost of sales | 6.80%-1.69B | 6.13%-3.67B | 1.42%-1.81B | -3.10%-3.91B | -2.11%-1.84B | -629.48%-3.79B | -650.70%-1.8B | -28.34%-519.38M | ---240.2M | -15.12%-404.69M |
| Operating expenses | 6.80%-1.69B | 6.13%-3.67B | 1.42%-1.81B | -3.10%-3.91B | -2.11%-1.84B | -629.48%-3.79B | -650.70%-1.8B | -28.34%-519.38M | -240.2M | -15.12%-404.69M |
| Special items of gross profit | 40.54%289.57M | -31.34%474.04M | -33.11%206.04M | -20.54%690.42M | -29.32%308.01M | 401.19%868.86M | 447.21%435.75M | 15.49%173.36M | --79.63M | 23.45%150.1M |
| Gross profit | 35.10%295.91M | -30.69%491.04M | -29.90%219.03M | -19.77%708.46M | -29.48%312.47M | 401.99%882.99M | 449.75%443.11M | 17.10%175.9M | 80.6M | 23.57%150.21M |
| Selling expenses | -46.20%-2.65M | -67.76%-4.86M | -27.30%-1.81M | 0.17%-2.89M | -38.75%-1.43M | -436.85%-2.9M | -338.89%-1.03M | 14.56%-540K | ---234K | 84.93%-632K |
| Administrative expenses | 8.43%-103.38M | -2.65%-231.53M | -2.66%-112.9M | 32.56%-225.55M | 33.14%-109.97M | -677.27%-334.44M | -866.16%-164.49M | -78.00%-43.03M | ---17.03M | -47.45%-24.17M |
| Research and development expenses | ---3.3M | ---13.59M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Revaluation surplus | 23.64%-462.43M | -88.75%-1.26B | -46.06%-605.59M | -322.22%-667.88M | -3,332.87%-414.62M | -1,297.87%-158.18M | -23.33%12.83M | 20.10%-11.32M | --16.73M | -17.56%-14.16M |
| -Changes in the fair value of other assets | 23.64%-462.43M | -88.75%-1.26B | -46.06%-605.59M | -322.22%-667.88M | -3,332.87%-414.62M | -1,297.87%-158.18M | -23.33%12.83M | 20.10%-11.32M | --16.73M | -17.56%-14.16M |
| Impairment and provision | ---- | 100.02%20K | ---- | ---97M | ---- | ---- | ---- | ---4.9M | ---- | ---- |
| -Other impairment is provision | ---- | 100.02%20K | ---- | ---97M | ---- | ---- | ---- | ---4.9M | ---- | ---- |
| Special items of operating profit | -25.91%-238.2M | 30.31%-422.69M | 30.50%-189.18M | 29.85%-606.56M | 36.90%-272.2M | -437.59%-864.61M | -515.38%-431.37M | -9.00%-160.83M | ---70.1M | -21.58%-147.55M |
| Operating profit | 25.55%-514.05M | -61.79%-1.44B | -42.14%-690.44M | -86.83%-891.42M | -244.63%-485.74M | -966.98%-477.14M | -1,513.29%-140.95M | -23.18%-44.72M | 9.97M | -11.96%-36.31M |
| Financing cost | -2.15%-147.03M | -4.96%-282.3M | -14.38%-143.94M | -22.36%-268.95M | -34.21%-125.84M | -915.93%-219.8M | -976.43%-93.77M | -59.02%-21.64M | ---8.71M | 5.55%-13.61M |
| Special items of earning before tax | 40.54%289.57M | -31.34%474.04M | -33.11%206.04M | -20.54%690.42M | -29.32%308.01M | 401.19%868.86M | 447.21%435.75M | 15.49%173.36M | --79.63M | 23.45%150.1M |
| Earning before tax | 40.87%-371.51M | -166.09%-1.25B | -106.98%-628.34M | -373.35%-469.95M | -251.01%-303.58M | 60.67%171.92M | 148.52%201.04M | 6.80%107.01M | 80.89M | 34.02%100.19M |
| Tax | 18.19%-6.28M | 0.34%-18.78M | -11.16%-7.67M | -36.08%-18.84M | -0.15%-6.9M | -468.82%-13.85M | -709.64%-6.89M | -118.49%-2.43M | ---851K | -777.17%-1.11M |
| After-tax profit from continuing operations | 40.60%-377.78M | -159.68%-1.27B | -104.85%-636.01M | -409.21%-488.79M | -259.92%-310.48M | 51.17%158.08M | 142.55%194.15M | 5.54%104.57M | 80.04M | 32.76%99.08M |
| After-tax profit from non-continuing business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 54.14%-3.24M |
| Earning after tax | 40.60%-377.78M | -159.68%-1.27B | -104.85%-636.01M | -409.21%-488.79M | -259.92%-310.48M | 51.17%158.08M | 142.55%194.15M | 9.11%104.57M | 80.04M | 41.84%95.84M |
| Profit attributable to shareholders | 40.60%-377.78M | -159.68%-1.27B | -104.85%-636.01M | -409.21%-488.79M | -259.92%-310.48M | 51.17%158.08M | 142.55%194.15M | 9.11%104.57M | 80.04M | 41.84%95.84M |
| Basic earnings per share | 40.66%-0.54 | -158.57%-1.81 | -106.82%-0.91 | -380.00%-0.7 | -241.94%-0.44 | 47.06%0.25 | 29.17%0.31 | -41.38%0.17 | 0.24 | 45.00%0.29 |
| Diluted earnings per share | 40.66%-0.54 | -158.57%-1.81 | -106.82%-0.91 | -380.00%-0.7 | -241.94%-0.44 | 47.06%0.25 | 29.17%0.31 | -41.38%0.17 | 0.24 | 45.00%0.29 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | USD | USD | USD |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.